Drugmaker Lupin inks a strategic deal with NeuClone, a Sydney-based private speciality lifescience company, for cell line technology on Wednesday. The market was expecting some announcements from Lupin, but the expectations went wild in terms of acquisitions and buyouts.
S Ramesh, CFO of Lupin, in an interview with CNBC-TV18
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
